These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8104306)

  • 1. Is Cremophor EL, solvent for paclitaxel, cytotoxic?
    Fjällskog ML; Frii L; Bergh J
    Lancet; 1993 Oct; 342(8875):873. PubMed ID: 8104306
    [No Abstract]   [Full Text] [Related]  

  • 2. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
    Fjällskog ML; Frii L; Bergh J
    Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
    Fujimoto S
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cremophor EL, solvent for paclitaxel, and toxicity.
    Liebmann J; Cook JA; Mitchell JB
    Lancet; 1993 Dec; 342(8884):1428. PubMed ID: 7901713
    [No Abstract]   [Full Text] [Related]  

  • 5. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
    Schuurhuis GJ; Broxterman HJ; Pinedo HM; van Heijningen TH; van Kalken CK; Vermorken JB; Spoelstra EC; Lankelma J
    Br J Cancer; 1990 Oct; 62(4):591-4. PubMed ID: 2223576
    [No Abstract]   [Full Text] [Related]  

  • 6. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
    Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
    Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
    Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
    Engblom P; Pulkkinen JO; Rantanen V; Hirvonen H; Kulmala J; Grènman R; Grènman S
    Eur J Cancer; 1999 Feb; 35(2):284-8. PubMed ID: 10448272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
    Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
    Cancer; 1997 Mar; 79(6):1225-33. PubMed ID: 9070502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
    Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
    Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines.
    Liebmann J; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB
    Cancer Chemother Pharmacol; 1994; 33(4):331-9. PubMed ID: 7904231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.
    Webster LK; Cosson EJ; Stokes KH; Millward MJ
    Br J Cancer; 1996 Feb; 73(4):522-4. PubMed ID: 8595168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.
    Terzis AJ; Thorsen F; Heese O; Visted T; Bjerkvig R; Dahl O; Arnold H; Gundersen G
    Br J Cancer; 1997; 75(12):1744-52. PubMed ID: 9192976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
    Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
    J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and toxicology of Cremophor EL diluent.
    Dorr RT
    Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.
    Liebmann JE; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB
    Br J Cancer; 1993 Dec; 68(6):1104-9. PubMed ID: 7903152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line.
    Chervinsky DS; Brecher ML; Hoelcle MJ
    Anticancer Res; 1993; 13(1):93-6. PubMed ID: 8097392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
    Ellis AG; Webster LK
    Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.